RESUMO
An atypical Advancing Wavelike Epitheliopathy case, consecutive to topical treatment for a 360º Conjunctival Intraepithelial Neoplasia, is presented. Mitomycin (0.2 mg/mL) and interferon (1 MUI/mL) drops were used. An atypical presentation, with migrating limbal focus, non clearly delimited in its hourly site through its evolution. Treated with flurometholone drops plus artificial tears, working to complete resolution.
Assuntos
Carcinoma in Situ , Neoplasias da Túnica Conjuntiva , Doenças da Córnea , Administração Tópica , Carcinoma in Situ/complicações , Carcinoma in Situ/tratamento farmacológico , Neoplasias da Túnica Conjuntiva/tratamento farmacológico , Doenças da Córnea/tratamento farmacológico , Humanos , Mitomicina/uso terapêuticoRESUMO
Se presenta un caso atípico de epiteliopatía progresiva en ondas consecutiva a tratamiento tópico de una neoplasia intraepitelial conjuntival en 360°. Se usaron colirios de mitomicina (0,2mg/ml) e interferón (1MUI/ml). Presentación atípica con foco limbar principal migratorio, y no claramente delimitado en su sitio horario a través de su evolución. Tratado con flurometolona y lágrimas artificiales, con resultado de resolución completa (AU)
An atypical Advancing Wavelike Epitheliopathy case, consecutive to topical treatment for a 360° Conjunctival Intraepithelial Neoplasia, is presented. Mitomycin (0.2mg/ml) and interferon (1MUI/ml) drops were used. An atypical presentation, with migrating limbal focus, non clearly delimited in its hourly site through its evolution. Treated with flurometholone drops plus artificial tears, working to complete resolution (AU)
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Carcinoma in Situ/tratamento farmacológico , Neoplasias da Túnica Conjuntiva/tratamento farmacológico , Neoplasias da Túnica Conjuntiva/complicações , Antibióticos Antineoplásicos/administração & dosagem , Interferons/administração & dosagem , Mitomicina/administração & dosagem , Doenças da Córnea/tratamento farmacológico , Administração TópicaRESUMO
CLINICAL CASE: An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour. DISCUSSION: Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP.
Assuntos
Inibidores da Angiogênese/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Degeneração Macular/tratamento farmacológico , Neovascularização Retiniana/tratamento farmacológico , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados , Bevacizumab , Humanos , Injeções , Degeneração Macular/patologia , Masculino , Neovascularização Retiniana/patologia , Corpo VítreoRESUMO
Caso clínico: Paciente varón de 81 años con proliferación angiomatosa retiniana (PAR) en estadio 2 identificado mediante angiografía fluoresceínica y tomografía de coherencia óptica (OCT) y con agudeza visual (AV) de 20/40. Una semana tras la inyección intravítrea de bevacizumab (1,25 mg), la AV mejoró a 20/25, y la OCT demostró reducción del edema intrarretiniano y del desprendimiento del epitelio pigmentario. Tres meses tras la inyección no se detectó ninguna complicación a nivel ocular, la AV era de 20/20 y la OCT mostraba un contorno macular prácticamente normal. Discusión: La inyección intravítrea de bevacizumab puede aportar una nueva opción terapéutica para los pacientes con PAR
Clinical case: An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour. Discussion: Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP
